Drug Profile
IMT 1012
Alternative Names: IMT-1012; IMT-1012 Immunotherapeutic vaccine; OCPM immunotherapeutic vaccineLatest Information Update: 28 Apr 2018
Price :
$50
*
At a glance
- Originator Immunotope
- Developer Duke University; Immunotope
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Breast cancer; Ovarian cancer
Most Recent Events
- 28 Apr 2018 No recent reports of development identified for phase-I development in Breast-cancer in USA (SC, Injection)
- 28 Apr 2018 No recent reports of development identified for phase-I development in Ovarian-cancer in USA (SC, Injection)
- 13 Aug 2008 IMT 1012 is still in active development